Calypte(765254) scheint aufzuerstehen!

 

 

aber ganz schwach die Umsätze...

88.000 bei ,15Cent....das ist ja nicht gerade..ein wahnsinnsumsatzniveau...  

 

nicht begriffen, dass das ding eine totgeburt ist. ihr werdet es auch nie begreifen, auch nicht nach den nächsten quartalszahlen, die vielleicht schon am 15.08. kommen.

dann geht es nämlich wieder unter die 0,10$ zum gap-close von direkt 2 gaps...


mann mann mann mann ...  

Calypte Announces Second Quarter 2007 Results



LAKE OSWEGO, Ore.--(BUSINESS WIRE)--

Calypte Biomedical Corporation (OTCBB: CBMC), a manufacturer of medical diagnostic tests for the rapid detection of antibodies to the human immunodeficiency virus (HIV), announced today its financial results for the quarter ended June 30, 2007.

For the quarter ended June 30, 2007 Calypte recorded revenues of $282,000, compared with $49,000 in the second quarter of 2006. The net loss for the quarter was approximately $0.8 million, or $0.00 per common share, in 2007 compared with a net loss of approximately $3.7 million or $0.02 per common share in 2006. Net loss for the quarter includes net non-cash selling, general and administrative and interest (income) expense totaling $(0.6) million in 2007 and $2.5 million in 2006.

For the six-month period ended June 30, 2007, revenues totaled $334,000 versus revenues of $140,000 for the same period in 2006. The net loss was $3.6 million or $0.01 per common share for the six-months ended June 30, 2007, compared to a net loss of $7.1 million or $0.04 per common share for the same period in 2006. The net loss for the six-month period ended June 30, 2007 and 2006 includes non-cash selling, general and administrative and interest expense totaling $1.1 million and $4.6 million, respectively.

The Company ended the second quarter with cash and cash equivalents of approximately $3.2 million.  

gemeinde. das zweite gap ist zu. kein wunder, bei den gruselzahlen trotz aller ominösen umsatzankündigungen im vorjahr...

Time & Sales most recent  next page
Rec. Time Action Price Volume
10:23:02 AM Bid 0.112  5000  
10:18:14 AM Bid 0.115  5000  
10:18:14 AM Bid 0.112  5000  
10:15:30 AM Trade 0.115  5600  
10:15:20 AM Bid 0.115  5000  
10:15:20 AM Ask 0.124  5000  
10:15:20 AM Trade 0.11  15000  
10:14:06 AM Bid 0.112  5000  
10:13:50 AM Trade 0.115  5000  
10:13:40 AM Trade 0.115  10000  
10:13:40 AM Bid 0.111  5000  
10:11:04 AM Trade 0.11  17810  
10:11:00 AM Trade 0.115  17750  
10:09:34 AM Trade 0.11  4000  
10:07:32 AM Ask 0.115  5000  
10:05:42 AM Trade 0.12  542  
10:05:42 AM Trade 0.12  2650  
10:05:32 AM Trade 0.12  7500  
10:05:32 AM Trade 0.12  16500  
10:05:32 AM Trade 0.12  16890  
10:05:32 AM Ask 0.12  5000  
10:05:30 AM Bid 0.11  5000  
10:04:42 AM Trade 0.12  5000  

das erste zwischen 0,08 - 0,089$ wird in kürze geschlossen...  

 

 

Calypte Biomedical Corporation (OTCBB: CBMC), a manufacturer of medical diagnostic tests for the rapid detection of antibodies to the human immunodeficiency virus (HIV), announced today its support for the guidance policy unveiled last week by the National AIDS Control Council (NACC) of Kenya gives Kenyans personal control over their HIV testing and encourages them to use non-invasive tests such as HIV-1/2 OMT (oral fluid) rapid tests. Calypte has provided Kenya, through the National AIDS and STD Control Program (NASCOP) of the Ministry of Health, 10,000 Aware(R) HIV-1/2 OMT (oral fluid) rapid tests which will be available to the public.
"An important facility or tool (is) to identify who needs to be treated - the sooner the better - and thereby making an important contribution to the fight against HIV/AIDS," His Excellency Peter Ogego, Kenyan Ambassador to the United States, noted at the time of accepting of Calypte OMT kits while in Washington DC..

Mr. Roger I. Gale, Calypte's Chairman and Chief Executive Officer commented, "The Republic of Kenya is now expanding its HIV/AIDS testing, which up to now has been blood-based testing, with the availability of simple, accurate non-invasive tests such as our Aware(R) HIV-1/2 oral fluid rapid tests. Testing is the best way to identify people living with HIV/AIDS who need to enter treatment or intervention programs. The Kenyan government provides access to antiretroviral drugs to people living with HIV/AIDS at no-cost, and we are pleased to be associated with the continuing improvement in the HIV situation in Kenya."

 

 

Da hält Gale doch Wort. Es wird ein neuer Markt nach dem Anderen erschlossen!
Nur eine Frage der Zeit, wenn die Umsätze steigen.
Mit etwas Geduld steigt Caly in große Höhen. Ich glaube dran!  

 

Wird also mal wieder Calypte durch´s Dorf geprügelt.... Naja, es gibt immer wieder Leute, die solchen Aktien tatsächlich etwas zutrauen. Was soll´s, manche haben ja Spaß am Geldverbrennen....

Gruß Carsten  

 

 

 

 

Umsätze der Aktien heute bisher?  

 

... und da wurde gemeldet, dass sich der Umsatz zum (zugegeben schwachen) Vorquartal etwa vervierfacht hat. Verlust je Aktie von 0,03 Cent auf 0,0 Cent gefallen!